FLT3 and leukemia: Upon treatment with the kinase inhibitor crenolanib (Figure 1), which blocks the activity of the oncogenic transmembrane protein FMS-like tyrosine kinase 3 (FLT3) on leukemia cells, augmented surface expression of FLT3 could be observed specifically on FLT3-ITD+ AML cells [26].